Treatment with the Australian company’s mesenchymal precursor cell (MPC) product, MPC-300-IV, was deemed well tolerated with no serious side effects or infusion-related adverse events in the 48-patient, 12-week Phase II study, the company says.
Among patients previously treated with at least one biologic drug, the common measure of 20% relief of signs and symptoms of the arthritis, known as ACR20, was achieved by 55% of those who received an infusion of 2 million cells per kilogram of weight. That compared with 33% in the placebo group who achieved ACR20.
The higher bar of ACR70, or 70% improvement, was achieved by 36% after one infusion of the Mesoblast treatment, compared with no patients in the placebo group who reported such an improvement.
The cell treatment also led to improvements in measures of physical function and overall disease activity versus placebo, the company said.
“The safety and efficacy results of this study are very encouraging and suggest that Mesoblast’s cell therapy has the potential to fill the major unmet medical need” for patients who cannot take biologic treatments, Dr. Allan Gibofsky, rheumatologist at Hospital for Special Surgery in New York, says in a statement.
Mesoblast, which is 14.6% owned by Teva Pharmaceutical Industries, says it plans to line up a partner to help it move the treatment into larger Phase III trials.
About one third of patients either do not respond sufficiently or cannot tolerate popular biologic treatments for rheumatoid arthritis, such as adalimumab, the world’s top-selling prescription medicine, creating a need for new therapy options.
To be competitive with current medicines, new treatments must address both pain and disease progression.